Organon & Co. (OGN) Earnings Call Analysis
NYSE · Healthcare · Drug Manufacturers - General
Earnings Reports
-
Organon (OGN) Q4 2025: $200M Cost Cuts Defend Margins Amid 16% Women’s Health Decline
June 15, 2026
-
Organon (OGN) Q3 2025: Respiratory Weakness Drives $75M Guidance Cut, Portfolio Reshuffle Signals Caution
November 10, 2025
-
Organon (OGN) Q2 2025: Biosimilars Up 68% as Debt Repayment Accelerates Deleveraging Path
August 05, 2025
-
Organon (OGN) Q1 2025: Dividend Cut Unlocks $200M for Debt, Shifting Capital Allocation Playbook
July 04, 2025